Todd M Cooper
Overview
Explore the profile of Todd M Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zarnegar-Lumley S, Alonzo T, Gerbing R, Othus M, Sun Z, Ries R, et al.
Blood Adv
. 2023 Jun;
7(19):5941-5953.
PMID: 37267439
Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the...
12.
Badawi M, Menon R, Place A, Palenski T, Sunkersett G, Arrendale R, et al.
J Cancer
. 2023 May;
14(7):1151-1156.
PMID: 37215448
Infiltration of malignant cells into the central nervous system in hematological malignancies correlates with poor clinical outcomes. Investigations into the penetration of venetoclax into the central nervous system have been...
13.
Stevens A, Schafer E, Li M, Terrell M, Rashid R, Paek H, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831684
Survival of pediatric AML remains poor despite maximized myelosuppressive therapy. The (PJP)-treating medication atovaquone (AQ) suppresses oxidative phosphorylation (OXPHOS) and reduces AML burden in patient-derived xenograft (PDX) mouse models, making...
14.
Comprehensive molecular and clinical characterization of fusions in pediatric acute myeloid leukemia
Bertrums E, Smith J, Harmon L, Ries R, Wang Y, Alonzo T, et al.
Haematologica
. 2023 Feb;
108(8):2044-2058.
PMID: 36815378
NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions,...
15.
Huang B, Smith J, Farrar J, Wang Y, Umeda M, Ries R, et al.
Nat Commun
. 2022 Sep;
13(1):5487.
PMID: 36123353
Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor outcomes and relapse risk prediction approaches have not changed significantly in decades. To build a robust transcriptional risk...
16.
Pommert L, Cooper T, Gerbing R, Brodersen L, Loken M, Gamis A, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158884
International Working Group (IWG) and European LeukemiaNet (ELN) response definitions are utilized to evaluate the efficacy of new agents for childhood acute myeloid leukemia (AML) for regulatory purposes. However, these...
17.
Tasian S, Silverman L, Whitlock J, Sposto R, Loftus J, Schafer E, et al.
Haematologica
. 2022 Feb;
107(10):2295-2303.
PMID: 35112552
Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling is commonly dysregulated in acute lymphoblastic leukemia (ALL). The TACL2014-001 phase I trial of the mTOR inhibitor temsirolimus in combination with cyclophosphamide...
18.
Lamble A, Brodersen L, Alonzo T, Wang J, Pardo L, Sung L, et al.
J Clin Oncol
. 2021 Dec;
40(3):252-261.
PMID: 34855461
Purpose: Increased CD123 surface expression has been associated with high-risk disease characteristics in adult acute myeloid leukemia (AML), but has not been well-characterized in childhood AML. In this study, we...
19.
Huang B, Smith J, Wang Y, Taghizadeh K, Leonti A, Ries R, et al.
Blood Adv
. 2021 Sep;
5(23):4963-4968.
PMID: 34547772
No abstract available.
20.
Tarlock K, Lamble A, Wang Y, Gerbing R, Ries R, Loken M, et al.
Blood
. 2021 May;
138(13):1137-1147.
PMID: 33951732
Biallelic CEBPA mutations are associated with favorable outcomes in acute myeloid leukemia (AML). We evaluated the clinical and biologic implications of CEBPA-basic leucine zipper (CEBPA-bZip) mutations in children and young...